Silence Therapeutics Plc Stock Price, News & Analysis

Welcome to our dedicated page for Silence Therapeutics Plc news (Ticker: SLN), a resource for investors and traders seeking the latest updates and insights on Silence Therapeutics Plc stock.

Silence Therapeutics plc (Nasdaq: SLN) generates a steady flow of news as a global clinical-stage biotechnology company developing siRNA (short interfering RNA) therapies. Its updates focus on the progress of programs built on its proprietary mRNAi GOLD™ platform, which is designed to create precision engineered siRNAs that target and silence disease-associated genes in the liver.

Investors following SLN news can expect detailed coverage of clinical trial milestones, particularly for divesiran, the company’s first-in-class siRNA candidate for polycythemia vera (PV). Recent announcements describe additional Phase 1 data presented at major hematology meetings, durable hematocrit control and reduced need for phlebotomies in PV patients, and the completion of enrollment in the global, randomized SANRECO Phase 2 study.

Silence also issues news on its broader pipeline and strategy, including updates on zerlasiran for cardiovascular disease, extra-hepatic siRNA targeting work, and its collaboration program SLN312 licensed to AstraZeneca. Financial result press releases provide context on research and development spending, cash and investment balances, and the company’s stated cash runway expectations, alongside commentary on operational priorities.

Corporate governance and leadership developments feature in SLN news as well, such as changes to the Board of Directors, executive transitions and outcomes of shareholder votes at the annual general meeting. Conference participation announcements highlight company presentations at healthcare and investor events, where management discusses the siRNA platform, clinical data and pipeline priorities.

By monitoring this news page, readers can review a chronological record of Silence Therapeutics’ clinical, financial and corporate disclosures related to SLN, with an emphasis on the evolution of its siRNA programs in cardiovascular disease, hematology and rare diseases.